Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
Document Type
Journal Article
Publication Date
1-20-2024
Journal
Journal of the American Academy of Dermatology
DOI
10.1016/j.jaad.2023.12.065
Keywords
STRATUM; phase 3; phosphodiesterase 4 inhibitor; randomized controlled trial; roflumilast foam 0.3%; seborrheic dermatitis
Abstract
BACKGROUND: The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. OBJECTIVE: Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD). METHODS: In this phase 3, double-blinded trial, patients with SD were randomly assigned (2:1 ratio) to once-daily roflumilast foam 0.3% or vehicle foam for 8 weeks. The primary efficacy outcome was Investigator Global Assessment (IGA) Success at week 8, defined as IGA of 0 (Clear) or 1 (Almost Clear) plus ≥2-point improvement from baseline. Safety was also assessed. RESULTS: 79.5% of roflumilast-treated and 58.0% of vehicle-treated patients met the primary endpoint (P < .001); statistically significant differences in IGA Success also favored roflumilast at week 2 (roflumilast: 43.0%; vehicle: 25.7%; P < .001) and week 4 (roflumilast: 73.1%; vehicle: 47.1%; P < .001). Roflumilast was well-tolerated with a low rate of treatment-emergent adverse events. LIMITATIONS: Study limitations include the 8-week treatment period for this chronic condition. CONCLUSIONS: Once-daily roflumilast foam was superior to vehicle in leading to IGA of Clear or Almost Clear plus ≥2-point improvement from baseline at 8 weeks in patients with SD. Longer trials are needed to determine durability and safety of roflumilast foam in SD.
APA Citation
Blauvelt, Andrew; Draelos, Zoe D.; Stein Gold, Linda; Alonso-Llamazares, Javier; Bhatia, Neal; DuBois, Janet; Forman, Seth B.; Gooderham, Melinda; Green, Lawrence; Guenthner, Scott T.; Hebert, Adelaide A.; Lain, Edward; Moore, Angela Y.; Papp, Kim A.; Zirwas, Matthew; Kato, Saori; Snyder, Scott; Krupa, David; Burnett, Patrick; Berk, David R.; and Chu, David H., "Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial" (2024). GW Authored Works. Paper 4146.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4146
Department
Dermatology